Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site
To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration. Randomized crossover experiment; prospective study. Eleven healthy adult horses between...
Gespeichert in:
Veröffentlicht in: | Veterinary anaesthesia and analgesia 2011-07, Vol.38 (4), p.374-384 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 384 |
---|---|
container_issue | 4 |
container_start_page | 374 |
container_title | Veterinary anaesthesia and analgesia |
container_volume | 38 |
creator | Messenger, Kristen M Davis, Jennifer L LaFevers, Douglas H Barlow, Beth M Posner, Lysa P |
description | To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration.
Randomized crossover experiment; prospective study.
Eleven healthy adult horses between 6 and 20 years of age and weighing 487–592 kg.
In the first phase; buprenorphine was administered as a single IV or SL dose (0.006 mg kg−1) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model. In the second phase; the jugular and lateral thoracic veins were catheterized for simultaneous venous blood sampling, following a dose of 0.006 mg kg−1 SL buprenorphine. For both phases, plasma buprenorphine concentrations were measured using ultra-performance liquid chromatography with mass spectrometry. At each sampling period, horses were assessed for behavioral excitement and gastrointestinal motility.
Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours. Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg−1 minute−1 and volume of distribution at steady-state was 3.16 ± 0.65 L kg−1. Following IV administration, horses showed signs of excitement. Gastrointestinal sounds were decreased following both routes of administration; however, none of the horses exhibited signs of colic. There was a significant discrepancy between plasma buprenorphine concentrations measured in the jugular vein versus the lateral thoracic vein following phase 2, thus pharmacokinetic parameters following SL buprenorphine are not reported.
Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses. While buprenorphine is absorbed into the circulation following SL administration, jugular venous sampling gave a false measurement of the quantity absorbed and should not be used to study the uptake from SL administration. |
doi_str_mv | 10.1111/j.1467-2995.2011.00613.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_872132708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1467298716306729</els_id><sourcerecordid>872132708</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4643-4aeb32a72126b738c2b2b195efc4759f0f44493a34c0dc64880cdd479230c6613</originalsourceid><addsrcrecordid>eNqNkUtv1TAQhS0EoqXwF5B3rBL8SpwgNpdCH1IFAhXKbuQ4E65v88JOyu2_xyHlbsEbjzznnNF8JoRylvJ4Xu9SrnKdiLLMUsE4TxnLuUz3j8jxofH4UBf6iDwLYccY12XGnpIjwTPGpebHxF72kzd32A9zoKavaZir1vU_ZtPSah59bPhx63qkrqfbwQcMb-i4Nb4zdriN75Ozq9H1TTtjb5EODQ2mG5cYGtyEz8mTxrQBXzzcJ-Tr2Yfr04vk6tP55enmKrEqVzJRBispjBZc5JWWhRWVqHiZYWOVzsqGNUqpUhqpLKttroqC2bpWuhSS2Tzuf0JerbmjH37OGCboXLDYtqbHuB4UMVoKzYqoLFal9UMIHhsYveuMvwfOYCEMO1jgwQISFsLwhzDso_Xlw5C56rA-GP8ijYK3q-CXa_H-v4Ph22YTi2hPVrsLE-4PduNvIddSZ3Dz8Rwubt5__3L2-RpY1L9b9RjJ3jn0EKxbvqF2Hu0E9eD-vdRva9KvKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>872132708</pqid></control><display><type>article</type><title>Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Messenger, Kristen M ; Davis, Jennifer L ; LaFevers, Douglas H ; Barlow, Beth M ; Posner, Lysa P</creator><creatorcontrib>Messenger, Kristen M ; Davis, Jennifer L ; LaFevers, Douglas H ; Barlow, Beth M ; Posner, Lysa P</creatorcontrib><description>To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration.
Randomized crossover experiment; prospective study.
Eleven healthy adult horses between 6 and 20 years of age and weighing 487–592 kg.
In the first phase; buprenorphine was administered as a single IV or SL dose (0.006 mg kg−1) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model. In the second phase; the jugular and lateral thoracic veins were catheterized for simultaneous venous blood sampling, following a dose of 0.006 mg kg−1 SL buprenorphine. For both phases, plasma buprenorphine concentrations were measured using ultra-performance liquid chromatography with mass spectrometry. At each sampling period, horses were assessed for behavioral excitement and gastrointestinal motility.
Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours. Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg−1 minute−1 and volume of distribution at steady-state was 3.16 ± 0.65 L kg−1. Following IV administration, horses showed signs of excitement. Gastrointestinal sounds were decreased following both routes of administration; however, none of the horses exhibited signs of colic. There was a significant discrepancy between plasma buprenorphine concentrations measured in the jugular vein versus the lateral thoracic vein following phase 2, thus pharmacokinetic parameters following SL buprenorphine are not reported.
Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses. While buprenorphine is absorbed into the circulation following SL administration, jugular venous sampling gave a false measurement of the quantity absorbed and should not be used to study the uptake from SL administration.</description><identifier>ISSN: 1467-2987</identifier><identifier>EISSN: 1467-2995</identifier><identifier>DOI: 10.1111/j.1467-2995.2011.00613.x</identifier><identifier>PMID: 21501371</identifier><language>eng</language><publisher>Oxford, UK: Elsevier Ltd</publisher><subject>Administration, Sublingual ; analgesia ; Analgesics, Opioid - administration & dosage ; Analgesics, Opioid - blood ; Analgesics, Opioid - pharmacokinetics ; Animals ; Biological Availability ; Blood Chemical Analysis - methods ; Blood Chemical Analysis - veterinary ; buprenorphine ; Buprenorphine - administration & dosage ; Buprenorphine - analogs & derivatives ; Buprenorphine - blood ; Buprenorphine - pharmacokinetics ; Cross-Over Studies ; equine ; Horses - metabolism ; Injections, Intravenous - veterinary ; Jugular Veins ; Male ; opioids ; pharmacokinetics ; Prospective Studies ; sampling site</subject><ispartof>Veterinary anaesthesia and analgesia, 2011-07, Vol.38 (4), p.374-384</ispartof><rights>2011 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia.</rights><rights>2011 The Authors. Veterinary Anaesthesia and Analgesia. © 2011 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesiologists</rights><rights>2011 The Authors. Veterinary Anaesthesia and Analgesia. © 2011 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesiologists.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4643-4aeb32a72126b738c2b2b195efc4759f0f44493a34c0dc64880cdd479230c6613</citedby><cites>FETCH-LOGICAL-c4643-4aeb32a72126b738c2b2b195efc4759f0f44493a34c0dc64880cdd479230c6613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1467-2995.2011.00613.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1467-2995.2011.00613.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21501371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Messenger, Kristen M</creatorcontrib><creatorcontrib>Davis, Jennifer L</creatorcontrib><creatorcontrib>LaFevers, Douglas H</creatorcontrib><creatorcontrib>Barlow, Beth M</creatorcontrib><creatorcontrib>Posner, Lysa P</creatorcontrib><title>Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site</title><title>Veterinary anaesthesia and analgesia</title><addtitle>Vet Anaesth Analg</addtitle><description>To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration.
Randomized crossover experiment; prospective study.
Eleven healthy adult horses between 6 and 20 years of age and weighing 487–592 kg.
In the first phase; buprenorphine was administered as a single IV or SL dose (0.006 mg kg−1) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model. In the second phase; the jugular and lateral thoracic veins were catheterized for simultaneous venous blood sampling, following a dose of 0.006 mg kg−1 SL buprenorphine. For both phases, plasma buprenorphine concentrations were measured using ultra-performance liquid chromatography with mass spectrometry. At each sampling period, horses were assessed for behavioral excitement and gastrointestinal motility.
Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours. Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg−1 minute−1 and volume of distribution at steady-state was 3.16 ± 0.65 L kg−1. Following IV administration, horses showed signs of excitement. Gastrointestinal sounds were decreased following both routes of administration; however, none of the horses exhibited signs of colic. There was a significant discrepancy between plasma buprenorphine concentrations measured in the jugular vein versus the lateral thoracic vein following phase 2, thus pharmacokinetic parameters following SL buprenorphine are not reported.
Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses. While buprenorphine is absorbed into the circulation following SL administration, jugular venous sampling gave a false measurement of the quantity absorbed and should not be used to study the uptake from SL administration.</description><subject>Administration, Sublingual</subject><subject>analgesia</subject><subject>Analgesics, Opioid - administration & dosage</subject><subject>Analgesics, Opioid - blood</subject><subject>Analgesics, Opioid - pharmacokinetics</subject><subject>Animals</subject><subject>Biological Availability</subject><subject>Blood Chemical Analysis - methods</subject><subject>Blood Chemical Analysis - veterinary</subject><subject>buprenorphine</subject><subject>Buprenorphine - administration & dosage</subject><subject>Buprenorphine - analogs & derivatives</subject><subject>Buprenorphine - blood</subject><subject>Buprenorphine - pharmacokinetics</subject><subject>Cross-Over Studies</subject><subject>equine</subject><subject>Horses - metabolism</subject><subject>Injections, Intravenous - veterinary</subject><subject>Jugular Veins</subject><subject>Male</subject><subject>opioids</subject><subject>pharmacokinetics</subject><subject>Prospective Studies</subject><subject>sampling site</subject><issn>1467-2987</issn><issn>1467-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1TAQhS0EoqXwF5B3rBL8SpwgNpdCH1IFAhXKbuQ4E65v88JOyu2_xyHlbsEbjzznnNF8JoRylvJ4Xu9SrnKdiLLMUsE4TxnLuUz3j8jxofH4UBf6iDwLYccY12XGnpIjwTPGpebHxF72kzd32A9zoKavaZir1vU_ZtPSah59bPhx63qkrqfbwQcMb-i4Nb4zdriN75Ozq9H1TTtjb5EODQ2mG5cYGtyEz8mTxrQBXzzcJ-Tr2Yfr04vk6tP55enmKrEqVzJRBispjBZc5JWWhRWVqHiZYWOVzsqGNUqpUhqpLKttroqC2bpWuhSS2Tzuf0JerbmjH37OGCboXLDYtqbHuB4UMVoKzYqoLFal9UMIHhsYveuMvwfOYCEMO1jgwQISFsLwhzDso_Xlw5C56rA-GP8ijYK3q-CXa_H-v4Ph22YTi2hPVrsLE-4PduNvIddSZ3Dz8Rwubt5__3L2-RpY1L9b9RjJ3jn0EKxbvqF2Hu0E9eD-vdRva9KvKg</recordid><startdate>201107</startdate><enddate>201107</enddate><creator>Messenger, Kristen M</creator><creator>Davis, Jennifer L</creator><creator>LaFevers, Douglas H</creator><creator>Barlow, Beth M</creator><creator>Posner, Lysa P</creator><general>Elsevier Ltd</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201107</creationdate><title>Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site</title><author>Messenger, Kristen M ; Davis, Jennifer L ; LaFevers, Douglas H ; Barlow, Beth M ; Posner, Lysa P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4643-4aeb32a72126b738c2b2b195efc4759f0f44493a34c0dc64880cdd479230c6613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Administration, Sublingual</topic><topic>analgesia</topic><topic>Analgesics, Opioid - administration & dosage</topic><topic>Analgesics, Opioid - blood</topic><topic>Analgesics, Opioid - pharmacokinetics</topic><topic>Animals</topic><topic>Biological Availability</topic><topic>Blood Chemical Analysis - methods</topic><topic>Blood Chemical Analysis - veterinary</topic><topic>buprenorphine</topic><topic>Buprenorphine - administration & dosage</topic><topic>Buprenorphine - analogs & derivatives</topic><topic>Buprenorphine - blood</topic><topic>Buprenorphine - pharmacokinetics</topic><topic>Cross-Over Studies</topic><topic>equine</topic><topic>Horses - metabolism</topic><topic>Injections, Intravenous - veterinary</topic><topic>Jugular Veins</topic><topic>Male</topic><topic>opioids</topic><topic>pharmacokinetics</topic><topic>Prospective Studies</topic><topic>sampling site</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Messenger, Kristen M</creatorcontrib><creatorcontrib>Davis, Jennifer L</creatorcontrib><creatorcontrib>LaFevers, Douglas H</creatorcontrib><creatorcontrib>Barlow, Beth M</creatorcontrib><creatorcontrib>Posner, Lysa P</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Veterinary anaesthesia and analgesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Messenger, Kristen M</au><au>Davis, Jennifer L</au><au>LaFevers, Douglas H</au><au>Barlow, Beth M</au><au>Posner, Lysa P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site</atitle><jtitle>Veterinary anaesthesia and analgesia</jtitle><addtitle>Vet Anaesth Analg</addtitle><date>2011-07</date><risdate>2011</risdate><volume>38</volume><issue>4</issue><spage>374</spage><epage>384</epage><pages>374-384</pages><issn>1467-2987</issn><eissn>1467-2995</eissn><abstract>To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration.
Randomized crossover experiment; prospective study.
Eleven healthy adult horses between 6 and 20 years of age and weighing 487–592 kg.
In the first phase; buprenorphine was administered as a single IV or SL dose (0.006 mg kg−1) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model. In the second phase; the jugular and lateral thoracic veins were catheterized for simultaneous venous blood sampling, following a dose of 0.006 mg kg−1 SL buprenorphine. For both phases, plasma buprenorphine concentrations were measured using ultra-performance liquid chromatography with mass spectrometry. At each sampling period, horses were assessed for behavioral excitement and gastrointestinal motility.
Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours. Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg−1 minute−1 and volume of distribution at steady-state was 3.16 ± 0.65 L kg−1. Following IV administration, horses showed signs of excitement. Gastrointestinal sounds were decreased following both routes of administration; however, none of the horses exhibited signs of colic. There was a significant discrepancy between plasma buprenorphine concentrations measured in the jugular vein versus the lateral thoracic vein following phase 2, thus pharmacokinetic parameters following SL buprenorphine are not reported.
Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses. While buprenorphine is absorbed into the circulation following SL administration, jugular venous sampling gave a false measurement of the quantity absorbed and should not be used to study the uptake from SL administration.</abstract><cop>Oxford, UK</cop><pub>Elsevier Ltd</pub><pmid>21501371</pmid><doi>10.1111/j.1467-2995.2011.00613.x</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1467-2987 |
ispartof | Veterinary anaesthesia and analgesia, 2011-07, Vol.38 (4), p.374-384 |
issn | 1467-2987 1467-2995 |
language | eng |
recordid | cdi_proquest_miscellaneous_872132708 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
subjects | Administration, Sublingual analgesia Analgesics, Opioid - administration & dosage Analgesics, Opioid - blood Analgesics, Opioid - pharmacokinetics Animals Biological Availability Blood Chemical Analysis - methods Blood Chemical Analysis - veterinary buprenorphine Buprenorphine - administration & dosage Buprenorphine - analogs & derivatives Buprenorphine - blood Buprenorphine - pharmacokinetics Cross-Over Studies equine Horses - metabolism Injections, Intravenous - veterinary Jugular Veins Male opioids pharmacokinetics Prospective Studies sampling site |
title | Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T00%3A39%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20and%20sublingual%20buprenorphine%20in%20horses:%20pharmacokinetics%20and%20influence%20of%20sampling%20site&rft.jtitle=Veterinary%20anaesthesia%20and%20analgesia&rft.au=Messenger,%20Kristen%20M&rft.date=2011-07&rft.volume=38&rft.issue=4&rft.spage=374&rft.epage=384&rft.pages=374-384&rft.issn=1467-2987&rft.eissn=1467-2995&rft_id=info:doi/10.1111/j.1467-2995.2011.00613.x&rft_dat=%3Cproquest_cross%3E872132708%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=872132708&rft_id=info:pmid/21501371&rft_els_id=S1467298716306729&rfr_iscdi=true |